Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Cited by (1,019)

Items 101–200 of 1,019

1. HDL Function, Dysfunction, and Reverse Cholesterol Transport
   E. Fisher, Jonathan E. Feig, B. Hewing, S. Hazen, Jonathan D. Smith · 2012 · Arteriosclerosis, Thrombosis and Vascular Biology
2. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
   Fox, Caroline S., Golden, Sherita Hill, Anderson, Cheryl, Bray, George A., Burke, Lora E., de Boer, Ian H., Deedwania, Prakash, Eckel, Robert H., Ershow, Abby G., Fradkin, Judith et al. · 2015 · Circulation
3. An abundant dysfunctional apolipoprotein A1 in human atheroma
   Ying R. Huang, Joseph A. DiDonato, Bruce S. Levison, Dave Schmitt, Lin Li, Yuping Wu, Jennifer A. Buffa, Timothy Kim, Gary S. Gerstenecker, Xiaodong Gu et al. · 2014 · Nature Medicine
4. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
   Frederick Johan Raal, Robert Patrick Giugliano, Marc Steven Sabatine, Michael J. Koren, Gisle Langslet, Harold Edward Bays, Dirk Jacobus Blom, Mats Eriksson, Ricardo E. Dent, Scott M. Wasserman et al. · 2014 · Journal of the American College of Cardiology
5. HDL-targeted therapies: progress, failures and future
   Kingwell, Bronwyn A., Chapman, M. John, Kontush, Anatol, Miller, Norman E. · 2014 · Nature Reviews Drug Discovery
6. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond
   AMY SANGHAVI SHAH, Lirong Tan, Jason Lu Long, William Sean Davidson · 2013 · Journal of Lipid Research
7. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
   Scott M. Grundy · 2013 · Journal of clinical lipidology
8. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
   Ballantyne, Christie M., Bays, Harold E., Kastelein, John J., Stein, Evan, Isaacsohn, Jonathan L., Braeckman, Rene A., Soni, Paresh N. · 2012 · The American Journal of Cardiology
9. High-density lipoproteins: A consensus statement from the National Lipid Association
   Toth, Peter P., Barter, Philip J., Rosenson, Robert S., Boden, William E., Chapman, M. John, Cuchel, Marina, D'Agostino, Ralph B., Davidson, Michael H., Davidson, W. Sean, Heinecke, Jay W. et al. · 2013 · Journal of Clinical Lipidology
10. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
    Marlys L. Koschinsky, Archna Bajaj, Michael B. Boffa, Dave L. Dixon, Keith C. Ferdinand, Samuel S. Gidding, Edward Allen Gill, Terry A. Jacobson, Erin D. Michos, Maya S. Safarova et al. · 2024 · Journal of clinical lipidology
11. High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions
    Dennis T. Ko, David Andrew Alter, Helen Guo, Maria Koh, Geoffrey Lau, Peter C. Austin, Gillian L. Booth, William E. Hogg, Cynthia Anne Jackevicius, Douglas S. Lee et al. · 2016 · Journal of the American College of Cardiology
12. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Das, Sandeep R., Echouffo-Tcheugui, Justin B. et al. · 2025 · Diabetes Care
13. Using Mendelian Randomization to Improve the Design of Randomized Trials
    Ference, Brian A., Holmes, Michael V., Smith, George Davey · 2021 · Cold Spring Harbor Perspectives in Medicine
14. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association
    Barbara S. Wiggins, Joseph J. Saseen, Robert Lee Page II, Brent N. Reed, Kevin Sneed, John B. Kostis, David E. Lanfear, Salim S. Virani, Pamela Bowe Morris · 2016 · Circulation
15. 8. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2016 · Diabetes Care
16. Racial/ethnic differences in dyslipidemia patterns
    Frank, Ariel T.H., Zhao, Beinan, Jose, Powell O., Azar, Kristen M.J., Fortmann, Stephen P., Palaniappan, Latha P. · 2014 · Circulation
17. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
    Scott M. Grundy, Hidenori Arai, Philip J. Barter, Thomas P. Bersot, D. J. Betteridge, Rafael Carmena, Ada M. Cuevas, Michael H. Davidson, Jacques J. Genest, Y. Antero Kesäniemi et al. · 2013 · Journal of clinical lipidology
18. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
    Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge R. Kizer, Lyle G. Best, Barbara V. Howard · 2017 · Diabetes Care
19. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
    Shipra Agrawal, Joshua J. Zaritsky, Alessia Fornoni, William E. Smoyer · 2017 · Nature Reviews Nephrology
20. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
    Pradhan, Aruna D., Paynter, Nina P., Everett, Brendan M., Glynn, Robert J., Amarenco, Pierre, Elam, Marshall, Ginsberg, Henry, Hiatt, William R., Ishibashi, Shun, Koenig, Wolfgang et al. · 2018 · American Heart Journal
21. Systematic review and meta‐analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors
    Santos, F. L., Esteves, S. S., da Costa Pereira, A., Yancy Jr, W. S., Nunes, J. P. L. · 2012 · Obesity Reviews
22. Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
    John J. Albers, April E Slee, Kevin D. O’Brien, Jennifer G. Robinson, Moti L. Kashyap, Peter O. Kwiterovich, Ping Xu, Santica M. Marcovina · 2013 · Journal of the American College of Cardiology
23. Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Macrophages Increases Inflammation and Accelerates Atherosclerosis in Mice
    Westerterp, Marit, Murphy, Andrew J., Wang, Mi, Pagler, Tamara A., Vengrenyuk, Yuliya, Kappus, Mojdeh S., Gorman, Darren J., Nagareddy, Prabhakara R., Zhu, Xuewei, Abramowicz, Sandra et al. · 2013 · Circulation Research
24. Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis: A Prospective Mendelian Randomization Study and Replication in a Case–Control Cohort
    Arsenault, Benoit J., Boekholdt, S. Matthijs, Dubé, Marie-Pierre, Rhéaume, Éric, Wareham, Nicholas J., Khaw, Kay-Tee, Sandhu, Manjinder S., Tardif, Jean-Claude · 2014 · Circulation: Cardiovascular Genetics
25. Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance
    Nita G. Forouhi, Ronald M. Krauss, Gary Taubes, Walter Churchill Willett · 2018 · BMJ
26. Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2
    Speer, Thimoteus, Rohrer, Lucia, Blyszczuk, Przemyslaw, Shroff, Rukshana, Kuschnerus, Kira, Kränkel, Nicolle, Kania, Gabriela, Zewinger, Stephen, Akhmedov, Alexander, Shi, Yi et al. · 2013 · Immunity
27. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
    Wadhera, Rishi K., Steen, Dylan L., Khan, Irfan, Giugliano, Robert P., Foody, JoAnne M. · 2016 · Journal of Clinical Lipidology
28. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
    Marston, Nicholas A., Giugliano, Robert P., Im, KyungAh, Silverman, Michael G., O’Donoghue, Michelle L., Wiviott, Stephen D., Ference, Brian A., Sabatine, Marc S. · 2019 · Circulation
29. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
    Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida et al. · 2023 · Journal of Atherosclerosis and Thrombosis
30. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
    Nathan D. Wong, Matthew Jay Budoff, Keith C. Ferdinand, Ian M Graham, Erin D. Michos, Tina K. Reddy, Michael D. Shapiro, Peter Paul Toth · 2022 · American Journal of Preventive Cardiology
31. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks
    Li, Xin-Min, Tang, Wai Hong Wilson, Mosior, Marian K., Huang, Ying, Wu, Yuping, Matter, William, Gao, Vivian, Schmitt, David, DiDonato, Joseph A., Fisher, Edward A. et al. · 2013 · Arteriosclerosis, Thrombosis, and Vascular Biology
32. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
33. Cardioprotective functions of HDLs
    Kerry‐Anne Rye, Philip J. Barter · 2013 · Journal of Lipid Research
34. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
    Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A. S., On behalf of the Guideline Development Group · 2014 · BMJ
35. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
36. Lipoprotein(a) and cardiovascular disease
    Børge Grønne Nordestgaard, Anne Langsted · 2024 · The Lancet
37. Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities
    K Mahdy Ali, Anna Wonnerth, Kurt Huber, Johann Wojta · 2012 · British Journal of Pharmacology
38. High-Density Lipoprotein
    Thomas Felix Lüscher, Ulf Landmesser, Arnold von Eckardstein, Alan M. Fogelman · 2014 · Circulation Research
39. Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
    Joe M. Chehade, Margaret Gladysz, Arshag D. Mooradian · 2013 · Drugs
40. Targeting inflammation in metabolic syndrome
    Welty, Francine K., Alfaddagh, Abdulhamied, Elajami, Tarec K. · 2016 · Translational Research
41. Imaging Atherosclerosis
    Jason M. Tarkin, Marc Richard Dweck, Nicholas R. Evans, Richard A. P. Takx, Adam J. Brown, Ahmed A Tawakol, Zahi Adel Fayad, James H F Rudd · 2016 · Circulation Research
42. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
    Helen H. Wang, Dong Ki Lee, Min Liu, Piero Portincasa, David Q.‐H. Wang · 2020 · Pediatric Gastroenterology Hepatology & Nutrition
43. Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications
    Valeria Gasperi, Matteo Sibilano, Isabella Savini, Maria Valeria Catani · 2019 · International Journal of Molecular Sciences
44. HDL cholesterol: reappraisal of its clinical relevance
    März, Winfried, Kleber, Marcus E., Scharnagl, Hubert, Speer, Timotheus, Zewinger, Stephen, Ritsch, Andreas, Parhofer, Klaus G., von Eckardstein, Arnold, Landmesser, Ulf, Laufs, Ulrich · 2017 · Clinical Research in Cardiology
45. LDL cholesterol: controversies and future therapeutic directions
    Ridker, Paul M · 2014 · The Lancet
46. G protein-coupled receptors for energy metabolites as new therapeutic targets
    Clara C. Blad, Cong Tang, Stefan Offermanns · 2012 · Nature Reviews Drug Discovery
47. Lipid management in patients with chronic kidney disease
    Charles Joseph Ferro, Patrick Barry Mark, Mehmet Kanbay, Pantelis A. Sarafidis, Gunnar Henrik Heine, Patrick Rossignol, Ziad A. Massy, Francesca Mallamaci, José Manuel Valdivielso, Jolanta Małyszko et al. · 2018 · Nature Reviews Nephrology
48. Is it time to revise the HDL cholesterol hypothesis?
    Daniel James Rader, Alan R. Tall · 2012 · Nature Medicine
49. Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts
    Shoaib Afzal, Peter Brøndum-Jacobsen, Stig E. Bojesen, Børge Grønne Nordestgaard · 2014 · BMJ
50. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial
    Margolis, Karen L., O’Connor, Patrick J., Morgan, Timothy M., Buse, John B., Cohen, Robert M., Cushman, William C., Cutler, Jeffrey A., Evans, Gregory W., Gerstein, Hertzel C., Grimm, Richard H. et al. · 2014 · Diabetes Care
51. Impact of Diet Composition on Blood Glucose Regulation
    Russell, Wendy R., Baka, Athanasia, Björck, Inger, Delzenne, Nathalie, Gao, Dan, Griffiths, Helen R., Hadjilucas, Ellie, Juvonen, Kristiina, Lahtinen, Sampo, Lansink, Mirian et al. · 2016 · Critical Reviews in Food Science and Nutrition
52. NAD + Metabolism in Cardiac Health, Aging, and Disease
    Mahmoud Abdellatif, Simon Sedej, Guido Kroemer · 2021 · Circulation
53. Effects of Icosapent Ethyl on Total Ischemic Events
    Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig et al. · 2019 · Journal of the American College of Cardiology
54. ATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation
    Marit Westerterp, Andrea E. Bochem, Laurent Yvan‐Charvet, Andrew James Murphy, Nan Wang, Alan R. Tall · 2014 · Circulation Research
55. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
    Lipinski, Michael J., Benedetto, Umberto, Escarcega, Ricardo O., Biondi-Zoccai, Giuseppe, Lhermusier, Thibault, Baker, Nevin C., Torguson, Rebecca, Brewer, H. Bryan, Waksman, Ron · 2016 · European Heart Journal
56. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
    Handelsman, Yehuda, Jellinger, Paul S., Guerin, Chris K., Bloomgarden, Zachary T., Brinton, Eliot A., Budoff, Matthew J., Davidson, Michael H., Einhorn, Daniel, Fazio, Sergio, Fonseca, Vivian A. et al. · 2020 · Endocrine Practice
57. Supplemental vitamins and minerals for CVD prevention and treatment
    Jenkins, David J.A., Spence, J. David, Giovannucci, Edward L., Kim, Young-in, Josse, Robert, Vieth, Reinhold, Blanco Mejia, Sonia, Viguiliouk, Effie, Nishi, Stephanie, Sahye-Pudaruth, Sandhya et al. · 2018 · Journal of the American College of Cardiology
58. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
    Victoria A Serhiyenko, Alexandr A. Serhiyenko · 2018 · World Journal of Diabetes
59. Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
    Jin, Qiao, Ma, Ronald Ching Wan · 2021 · Cells
60. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
    Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W. et al. · 2014 · European Heart Journal
61. Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment
    Varbo, Anette, Benn, Marianne, Nordestgaard, Børge G. · 2014 · Pharmacology & Therapeutics
62. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)
    G.B. John Mancini, Steven K. Baker, Jean Bergeron, DAVID H. FITCHETT, Jiri J Frohlich, Jacques J. Genest, Milan Gupta, Robert Alexander Hegele, Dominic S. Ng, Glen J. Pearson et al. · 2016 · Canadian Journal of Cardiology
63. High-density lipoproteins, reverse cholesterol transport and atherogenesis
    Henry J. Pownall, Corina Rosales, Baiba Kurins Gillard, Antonio M. Gotto · 2021 · Nature Reviews Cardiology
64. HIV infection and cardiovascular disease
    Hemkens, L. G., Bucher, H. C. · 2014 · European Heart Journal
65. HEART UK consensus statement on Lipoprotein(a): A call to action
    Jaimini Cegla, R. Dermot G. Neely, Michael W. France, Gordon A. Ferns, Christopher D. Byrne, Julian Halcox, Dev Borunendra Nath Datta, Nigel E. Capps, Carol C. Shoulders, Nadeem Qureshi et al. · 2019 · Atherosclerosis
66. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
    Zahid Ahmad, Poulabi Banerjee, Sara Hamon, Kuo‐Chen Chan, Aurelie Bouzelmat, William J. Sasiela, Robert C. Pordy, Scott J. Mellis, Hayes M. Dansky, Daniel A. Gipe et al. · 2019 · Circulation
67. Association between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-Risk Populations
    Liu, Chang, Dhindsa, Devinder, Almuwaqqat, Zakaria, Ko, Yi-An, Mehta, Anurag, Alkhoder, Ayman A., Alras, Zahran, Desai, Shivang Rajan, Patel, Krishan Jignesh, Hooda, Ananya et al. · 2022 · JAMA Cardiology
68. Hypertriglyceridemia and atherosclerosis
    Jia Peng, Fei Luo, Guiyun Ruan, Ran Peng, Xiangping Li · 2017 · Lipids in Health and Disease
69. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
    Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie, de Ferranti, Sarah D. et al. · 2026 · JACC
70. Coronary heart disease risk: Low-density lipoprotein and beyond
    Gabriel E. Shaya, Thorsten Martin Leucker, Steven Richard Jones, Seth Shay Martin, Peter Paul Toth · 2021 · Trends in Cardiovascular Medicine
71. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
    Toth, Peter · 2016 · Vascular Health and Risk Management
72. High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy
    Samia Mora, Robert J. Glynn, Paul M. Ridker · 2013 · Circulation
73. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
74. Lymphatic transport of high-density lipoproteins and chylomicrons
    Gwendalyn J. Randolph, N.E. Miller · 2014 · Journal of Clinical Investigation
75. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
    Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema, Amit Khera, Andrzej Stanislaw Kosinski, Jeffrey T. Kuvin · 2018 · Journal of the American College of Cardiology
76. 8. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2014 · Diabetes Care
77. Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
    Abraham Michael Lincoff, Jean‐Claude Tardif, Gregory G. Schwartz, Stephen James Nicholls, Lars Rydén, Bruce Charles Neal, Klas Malmberg, Hans Wedel, John B. Buse, Robert R. Henry et al. · 2014 · JAMA
78. Implications of altered NAD metabolism in metabolic disorders
    Okabe, Keisuke, Yaku, Keisuke, Tobe, Kazuyuki, Nakagawa, Takashi · 2019 · Journal of Biomedical Science
79. Novel Biological Functions of High-Density Lipoprotein Cholesterol
    Chieko Mineo, Philip W. Shaul · 2012 · Circulation Research
80. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
    Florian Kronenberg · 2016 · Cardiovascular Drugs and Therapy
81. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
    Constantine E. Kosmas, Ian Martinez, Andreas Sourlas, Kyriaki V. Bouza, Frederick N Campos, Verenisse Torres, Peter D. Montan, Eliscer Guzman · 2018 · Drugs in Context
82. Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products
    Dongdong Wang, Yang Yang, Yingnan Lei, Nikolay T. Tzvetkov, Xingde Liu, Andy Wai Kan Yeung, Suowen Xu, Atanas G. Atanasov · 2019 · Pharmacological Reviews
83. Management of hypertriglyceridemia
    Vinaya Simha · 2020 · BMJ
84. Translation of High-Density Lipoprotein Function Into Clinical Practice
    Robert S. Rosenson, H. Bryan Brewer, Benjamin J. Ansell, Philip J. Barter, M. John Chapman, Jay W. Heinecke, Anatol Kontush, Alan R. Tall, Nancy R. Webb · 2013 · Circulation
85. 9. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2017 · Diabetes Care
86. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events
    Amit V. Khera, Olga Demler, Steven J. Adelman, Heidi L. Collins, Robert J. Glynn, Paul M. Ridker, Daniel James Rader, Samia Mora · 2017 · Circulation
87. How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
    Welty, Francine K. · 2013 · Current Cardiology Reports
88. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
    Shapiro, Michael D., Fazio, Sergio · 2016 · Circulation Research
89. Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults
    Jerome L. Fleg, Daniel E. Forman, Kathy A. Berra, Vera Bittner, James A. Blumenthal, Michael A. Chen, Susan C. Cheng, Dalane W. Kitzman, Mathew S. Maurer, Michael W. Rich et al. · 2013 · Circulation
90. Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular disease
    Christian Besler, Thomas Felix Lüscher, Ulf Landmesser · 2012 · EMBO Molecular Medicine
91. American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
    Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Michael Davidson, DANIEL F. EINHORN, William Timothy Garvey et al. · 2013 · Endocrine Practice
92. Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
    Xiao-Hua Yu, Dawei Zhang, Xi‐Long Zheng, Chao‐Ke Tang · 2018 · Progress in Lipid Research
93. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
    Gusarova, Viktoria, Alexa, Corey A., Wang, Yan, Rafique, Ashique, Kim, Jee Hae, Buckler, David, Mintah, Ivory J., Shihanian, Lisa M., Cohen, Jonathan C., Hobbs, Helen H. et al. · 2015 · Journal of Lipid Research
94. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
    Michael J. Koren, Robert Patrick Giugliano, Frederick Johan Raal, DAVID R. SULLIVAN, Michael A. Bolognese, Gisle Langslet, Fernando Civeira, Ransi M. Somaratne, Patric Nelson, Thomas Liu et al. · 2013 · Circulation
95. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population
    Varbo, Anette, Freiberg, Jacob J, Nordestgaard, Børge G · 2015 · Clinical Chemistry
96. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
    Anne Grete Semb, Eirik Ikdahl, Grunde Wibetoe, Cynthia S. Crowson, Silvia Rollefstad · 2020 · Nature Reviews Rheumatology
97. Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
    Michelle L. O’Donoghue, David A. Morrow, Sotirios Tsimikas, Sarah Sloan, Angela F. Ren, Elaine B. Hoffman, Nihar R. Desai, Scott David Solomon, MICHAEL J. DOMANSKI, Kiyohito Arai et al. · 2013 · Journal of the American College of Cardiology
98. 2018 Guidelines for the management of dyslipidemia
    Eun‐Jung Rhee, Hyeon Chang Kim, Jae Hyeon Kim, Eun Young Lee, Byung Jin Kim, Eun Mi Kim, YoonJu Song, Jeong Hyun Lim, Byung Jin Kim, Seonghoon Choi et al. · 2019 · The Korean Journal of Internal Medicine
99. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol
    Xiao, Changting, Dash, Satya, Morgantini, Cecilia, Hegele, Robert A., Lewis, Gary F. · 2016 · Diabetes
100. SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis
     MacRae F. Linton, Huan Tao, Edward F. Linton, Patricia G. Yancey · 2017 · Trends in Endocrinology and Metabolism